112 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
of directors with respect to fiscal 2023 included:
drug safety, including the safety of clinical trial participants;
manufacturing and supply chain
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response … demonstrated a well-tolerated safety profile 1Amnolake® post-marketing surveillance data on file; 2Data presented at ASH 2017; 3de Botton S., et al
8-K
EX-99.2
5dah78ey23z
8 Jan 24
Regulation FD Disclosure
7:06am
8-K
EX-1.1
u1ct3 b22wf
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
424B5
z1yyof8m1vucbc
19 Dec 23
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
bg97 uvi5dj1k8m
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.2
d0mmlo0ey nj
6 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.2
chl2mngu
25 May 23
Regulation FD Disclosure
5:10pm
8-K
EX-99.1
9e3qh08ax9nqx ia
25 May 23
Regulation FD Disclosure
5:10pm
8-K
wra2sjw
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
EX-99.1
u9jf7r 291
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
EX-99.2
cm1jiitc6 9aqqsmds
12 Dec 22
Regulation FD Disclosure
7:48am